AAPS 2025 PharmSci 360 Meeting

Join RTI at the American Association of Pharmaceutical Sciences (AAPS) 2025 PharmSci 360 Meeting in San Antonio, Texas. This event brings together thousands of pharmaceutical scientists and researchers to foster conversations around the latest research and technologies to improve health. Topics include advancements in drug discovery, development, and manufacturing; preclinical and clinical sciences; bioanalytics and formulation. 

RTI at AAPS 2025 PharmSci 360

Speaking Events

Title: Harnessing In Vitro Models for NAMS-Based Inhalable Substance Safety Assessments
Speaker: Erin A. Huber
Date & Time: Nov. 12 | 9:00 - 9:30 a.m. CT 
Location: Room 225 AB

Dr. Huber will discuss how respiratory new approach methodologies (NAMs) can be used to improve the human relevance of drug development by integrating variability in effects of treatments across different individuals – a critical factor in drug safety and efficacy that cannot be evaluated by traditional animal models that are used in early drug development. She will provide data from her recent studies examining the impacts of improving the real-world relevance of experimental studies, test methods characterization, and inter-individual variability in complex human cell-based lung models. 

Title: Creating Community Connections to Enhance Clinical Research
Speaker: Nikki McKoy
Date & Time: Nov. 11 | 1:30 - 2:30 p.m. CT 
Location: Room 225 CD

Ms. McKoy will describe key concepts of community engagement and provide practical examples and lessons learned from engaging with communities. Successful community engagement improves clinical research, allowing new and effective interventions to reach the communities that need them the most.

Posters

Title: Formulation of a Teixobactin-Lipopeptide Hybrid as an Inhalable Dry Powder for the Treatment of Pulmonary Pan-Drug Resistant Bacteria Infections
Presenter: Leanna Levin
Date & Time: Nov. 12 | 11:30 a.m. - 12:30 p.m. CT

Ms. Levin's poster demonstrates a successful formulation of a novel antibiotic hybrid for ingale delivery using a dry powder inhaler, facilitating direct delivery to the lungs for treatment of pulmonary pan-drug resistant bacterial infections. This work was in collaboration with Ms. Levin's mentor, Dr. Sara Maloney Norcross.